Mirtazapin Ratiopharm (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action enhances overall serotonergic and noradrenergic neurotransmission, helping to improve mood and reduce depressive symptoms.

The appropriate dose of Mirtazapin Ratiopharm is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy and tolerability. Dosage adjustments are made according to professional medical judgment and current treatment guidelines.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mirtazapin Ratiopharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Ratiopharm (mirtazapine) belongs to the NaSSA class, which differs from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in stronger sedative effects and appetite stimulation, making it useful for patients with insomnia or weight loss, whereas SSRIs typically have fewer metabolic effects.

Mirtazapin Ratiopharm should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Mirtazapin Ratiopharm is taken orally, usually once daily in the evening, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise instructed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic dysfunction, hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, especially at the start of therapy. Patients should be monitored closely for any signs of these conditions.

Mirtazapin Ratiopharm is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and it should be avoided in individuals currently taking monoamine oxidase inhibitors. Caution is also advised for patients with severe hepatic impairment or uncontrolled cardiovascular disease.